Conventional Chemotherapy and Emerging Targeted Therapy for Advanced Adrenocortical Carcinoma

Author(s): Yun-Ze Xu, Yu Zhu

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 13 , Issue 2 , 2013

Become EABM
Become Reviewer
Call for Editor


Adrenocortical carcinoma (ACC) is a rare but typically aggressive malignancy. Radical surgery remains the potentially curative option. However, about one third of patients initially present with distant metastases. Regarding to chemotherapy, mitotane alone or in combination with cytotoxic drugs should be the first selection. Meanwhile, a phase lll clinical trial of etoposide, doxorubicin, cisplatin plus mitotane or streptozotocin plus mitotane is currently undergoing worldwide. The study on molecular pathogenesis of ACC is progressing. A lot of targeted therapies are also enrolled in preclinical investigations and clinical trials, including small-molecule tyrosine kinase inhibitors, antiangiogenic compounds. This article introduced the conventional chemotherapy, newly developed targeted therapy for advanced ACC.

Keywords: Advanced adrenocortical carcinoma, Chemotherapy, Mitotane, Molecular target, Target therapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [248 - 253]
Pages: 6
DOI: 10.2174/1871520611313020010
Price: $65

Article Metrics

PDF: 35